

UC Irvine

UC Irvine Previously Published Works

Title

A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior

Permalink

<https://escholarship.org/uc/item/9vg2k82g>

Authors

Thanos, Panayotis K

Robison, Lisa S

Steier, Jessica

et al.

Publication Date

2015-04-01

DOI

10.1016/j.pbb.2015.01.005

Peer reviewed



Contents lists available at ScienceDirect

Pharmacology, Biochemistry and Behavior

journal homepage: www.elsevier.com/locate/pharmbiochembeh

Q5 A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior

Q6 Panayotis K. Thanos^{a,*}, Lisa S. Robison^a, Jessica Steier^a, Yu Fen Hwang^a, Thomas Cooper^b, James M. Swanson^c, David E. Komatsu^d, Michael Hadjiargyrou^e, Nora D. Volkow^f

Q7 ^a Department of Psychology, Stony Brook University, Stony Brook, NY, United States

^b Nathan Kline Institute, Orangeburg, NY, United States

^c Department of Pediatrics, University of California, Irvine, United States

^d Department of Orthopaedics, Stony Brook University, Stony Brook, NY 11794-8181, United States

^e Department of Life Sciences, New York Institute of Technology, Old Westbury, NY 11568-8000, United States

^f Laboratory of Neuroimaging, NIAAA, NIH, Bethesda, MD, United States

1 1 A R T I C L E I N F O

12 Article history:

13 Received 25 September 2014

14 Received in revised form 31 December 2014

15 Accepted 9 January 2015

16 Available online xxxx

17 Keywords:

18 Methylphenidate

19 Ritalin

20 Attention deficit hyperactivity disorder

21 Psychostimulant

22 Dopamine transporter

A B S T R A C T

Most animal studies using methylphenidate (MP) do not administer it the same way it is administered clinically (orally), but rather by injection, resulting in an altered pharmacokinetic profile (i.e. quicker and higher peak concentrations). Here, we evaluated several oral-dosing regimens in rats, including dual-dose drinking, to mimic the clinical drug delivery profile. Using an 8-hour-limited-access-drinking-paradigm, MP solutions were delivered at different doses (20, 30, or 60 mg/kg/day; as well as dual-dosages of 4 and 10 mg/kg/day, 20 and 30 mg/kg/day, or 30 and 60 mg/kg/day, in which the low dose was administered in the first hour of drinking followed by 7 h of drinking the high dose). Blood was sampled and plasma was assayed for MP levels at many time points. Results showed that an 8-hour limited drinking of a dual-dosage 30/60 mg/kg MP solution achieved a pharmacokinetic profile similar to clinically administered doses of MP at the high end of the spectrum (peaking at ~30 ng/mL), while the 4/10 mg/kg MP dual-dosage produced plasma levels in the range produced by typically prescribed clinical doses of MP (peaking at ~8 ng/mL). Treatment with the higher dual-dosage (HD: 30/60 mg/kg) resulted in hyperactivity, while the lower (LD: 4/10 mg/kg) had no effect. Next, chronic effects of these dual-dosages were assessed on behavior throughout three months of treatment and one month of abstinence, beginning in adolescence. MP dose-dependently decreased body weight, which remained attenuated throughout abstinence. MP decreased food intake during early treatment, suggesting that MP may be an appetite suppressant and may also speed metabolism and/or suppress growth. Chronic HD MP resulted in hyperactivity limited during the dark cycle; decreased exploratory behavior; and increased anxiolytic behavior. These findings suggest that this dual-dosage-drinking-paradigm can be used to examine the effects of clinically relevant pharmacokinetic doses of MP, and that chronic treatment with such dosages can result in long-lasting developmental and behavioral changes.

© 2015 Elsevier Inc. All rights reserved.

Q9 1. Introduction

Methylphenidate (MP) remains one of the most widely prescribed drugs for the treatment of attention deficit hyperactivity disorder (ADHD) (Swanson and Volkow, 2008; Swanson and Volkow, 2009). In the last decade, the diagnosis rate of ADHD for youth aged 4 to 17 increased 41%, jumping to a national average in the United States of 11%, with two-thirds of diagnosed children being treated with psychostimulant medications (Bloom et al., 2012). Lifetime diagnosis (10% in girls and 19% in boys) and stimulant prescription rates

(~10% in boys) in high-school aged youth are even higher (Bloom et al., 2012). The new DSM-5 increasing the maximum age of symptom onset from 7 to 12, and reducing the number of criteria needed from six to five for adults (APA, 2013), will likely result in greater diagnosis rates across all age groups. MP is also used illegally as a study aid among high school and college students and is abused recreationally (McCabe et al., 2006; Wilens et al., 2008). Among college students in the United States, self-reported rates range from 1.5% to 31%, with the most nationally representative study estimating annual illicit stimulant use at ~4% (McCabe et al., 2005; Teter et al., 2006; Bogle and Smith, 2009; Garnier-Dykstra et al., 2012).

The increasing use and abuse of MP, particularly during critical stages of neurodevelopment, presents great concerns of subsequent neurobiological, developmental, and behavioral effects. Also of

* Corresponding author. Tel./fax: +1 631 632 4666.

E-mail address: peter.thanos@stonybrook.edu (P.K. Thanos).

concern is the capability of MP to produce cross-sensitization to the effects of other stimulant drugs (Pierce and Kalivas, 1997), as this phenomenon of cross-sensitization is hypothesized as a mechanism that increases vulnerability to polysubstance abuse later in life (Robinson and Berridge, 2001). These concerns raise the need for preclinical studies that assess possible consequences of MP treatment at doses that are clinically relevant. Preclinical studies have found significant effects of MP on neurochemistry (Brandon et al., 2003; Brandon and Steiner, 2003; Grund et al., 2006; Thanos et al., 2007; Robison et al., 2012), development (Robison et al., 2010; Komatsu et al., 2012), behavior (Kuczenski and Segal, 2001; Thanos et al., 2009; Robison et al., 2010; Zhu et al., 2010), and psychostimulant cross-sensitization and self-administration (Kuczenski and Segal, 2002; Torres-Reveron and Dow-Edwards, 2005; Thanos et al., 2007).

A major limitation of animal studies, however, is that the route of administration of MP is typically by injection and not oral as is used clinically (Volkow and Insel, 2003). Humans being treated for ADHD receive MP orally, either in the immediate release (IR) formulation administered two (b.i.d.) or three (t.i.d.) times daily, or in the extended release (ER) formulation administered once daily (q.d.) (Volkow and Swanson, 2003). In most animal studies, MP is administered intravenously (IV), intraperitoneally (IP), or subcutaneously. Studies have shown that these routes of MP administration differ significantly from oral administration, specifically with respect to magnitude of and time to peak serum concentration, half-life, and rate of elimination (Kuczenski and Segal, 2005), as well as absolute magnitude and time course of increases in extracellular DA and locomotor responses (Gerasimov et al., 2000; Kuczenski and Segal, 2001). Since these are key factors in the abuse liability of drugs (Volkow and Swanson, 2003), it is likely that administering MP in a fashion that leads to rapid peak serum and brain DA levels (such as IP or IV) might preferentially induce sensitization or other adaptations of the neural substrate in ways that oral MP (with its more gradual onset and reduced bioavailability), might not.

Doses of 0.5 to 5 mg/kg IP have been used in most rodent studies, and it has been reported that even an IP injection of 0.5 mg/kg would result in plasma concentrations at the highest end of the clinically-relevant spectrum (~40 ng/mL; equivalent to a 1.0 mg/kg dose in humans) and would peak within minutes post-injection rather than hours post-oral administration (Kuczenski and Segal, 2005). Additionally, many studies that have aimed to explore the effects of oral MP utilize the gavage method (Kuczenski and Segal, 2002; Justo et al., 2010), which can result in a significant stress response, as well as aspiration, and/or pulmonary injury in rats (Brown et al., 2000; Balcombe et al., 2004). Other studies have utilized voluntary oral consumption of MP (administered on oyster crackers or mixed with chow) to avoid these issues (LeBlanc-Duchin and Taukulis, 2007; Zhu et al., 2010); however, these methods also have some limitations. Oral administration results in peak serum concentration 15 min post-administration, and this concentration has been shown to drop by half within an additional 5 min (Patrick et al., 1984). The faster metabolism and shorter half-life of MP in rats compared to humans would therefore necessitate nearly constant dosing to maintain clinically relevant plasma concentrations. Therefore, the challenge addressed in the present study was to develop a method of administering MP to rodents that would produce a drug delivery profile similar to that achieved by clinical administration of MP. This means that the route of administration must be oral, and that plasma levels and profiles should resemble the patterns of dosing used in clinical practice (Swanson and Volkow, 2002). In the present study, we tested several oral dosing paradigms and chose two (a clinically-relevant low and high dose) for further examination of effects of chronic treatment (three months) on development and behavior in rats. Rats were also assessed following a one month abstinence period to determine whether any effects persisted beyond the cessation of treatment.

2. Materials and methods

2.1. Animals

Male Sprague–Dawley rats were obtained from Taconic Farms (Germantown, NY). On arrival, rats were single housed in a temperature- and humidity-controlled room on a reverse 12 hour light cycle (lights off 0800 h). Food access was provided ad libitum at all times during the experiment and consisted of standard laboratory rat chow (Purina). Food intake and body weight were recorded daily during chronic exposure and abstinence. Experiments were conducted in conformity with the National Academy of Science's Guide for the Care and Use of Laboratory Animals (NAS and NRC, 1996) and approved by the Brookhaven National Laboratory Institutional Animal Care and Use Committee protocols.

2.2. Drugs

Methylphenidate hydrochloride (Sigma-Aldrich, St Louis, MO) was mixed with distilled water to deliver respective experimental doses in the rats' daily drinking water.

2.3. Procedures

2.3.1. Determination of clinically relevant dosing regimens of MP

2.3.1.1. Drug administration. One week after arrival, rats were given limited access to water 8 h per day (8:00 h–16:00 h) in their home cages. This restricted access continued throughout the length of the experiment, except for the five days following an experimental blood draw when water access was ad libitum.

Different MP total daily doses were examined in this experiment ($n = 12/\text{group}$): 20, 30, and 60 mg/kg/day, as well as dual dosages of 4/10 mg/kg/day, 20/30 mg/kg/day, and 30/60 mg/kg/day, which were administered in daily drinking water. Specifically, in the dual dose groups, rats received the low dose of the MP solution for the first hour, followed by the higher dose of MP solution for the remaining 7 h. Concentrations of MP solution were calculated daily and individually for each rat based on the animal's weight and the average volume of the last three days' fluid consumption.

2.3.2. Blood sampling and MP assay

On each blood-sampling day, animals were given 8-hour access to their respectively dosed MP drinking solutions. Rats were sampled at various times ($T = 1, 2, 4, 6, 8,$ and 10 h post-initiation of drinking). The MP solution was withdrawn from all rats at $T = 8$.

Blood was collected in two ways: a) venipuncture from the lateral tail vein while the animal was awake and lightly restrained (this usually took less than 5 min); and b) terminal cardiac puncture under deep anesthesia. Blood obtained by either method was immediately placed in K_2EDTA -coated tubes and centrifuged. The plasma was drawn off and stored at -80°C until analysis occurred. A minimum of two weeks were allowed for recovery after each tail venipuncture, and no animal underwent more than two tail vein sampling procedures.

2.3.3. Locomotor activity

Rats were tested for locomotor responses to MP treatment, which was measured for three consecutive days in cages similar to their home cages (50 cm \times 25 cm \times 30 cm high) (Mini Mitter VitalView software; Bend, Oregon). The first day was used for habituation to the experimental room; this data was discarded, and the remaining two days of locomotor data were averaged for each animal. Data was binned so as to measure activity at $T = 0, 1, 2, 4, 6, 8,$ and 10 h post-initiation of drinking. Food was provided ad libitum, and the 8 h limited access drinking paradigm was kept in place during these tests.

2.3.4. Determination of developmental and behavioral effects of chronic MP and abstinence

2.3.4.1. *Drug administration.* Beginning at 4 weeks of age, rats were given limited access to their respective drinking solution for 8 h per day (9:00 h–17:00 h) in their home cages. This restricted access continued throughout the length of the experiment. Rats received either water (control), 4 mg/kg MP (low dose; LD) or 30 mg/kg MP (high dose; HD) during the first hour (09:00–10:00), and water (control), 10 mg/kg (LD) or 60 mg/kg MP (HD) for the remaining 7 h (10:00–17:00). Concentrations of MP solution were calculated daily and individually for each rat based on the animal's weight and the average volume of the last three days' fluid consumption. Rats were treated for three months with their respective treatment ($n = 24/\text{group}$), following which half of the rats in each treatment group underwent a one month abstinence period ($n = 12/\text{group}$), during which they were given only water to drink for the entire 8 h limited access drinking period daily.

2.3.4.2. *Open field locomotor activity.* Animals were run in an open-field arena photo beam activity monitoring system (Coulbourn Instruments, Allentown, PA) (dimensions 40.64 cm \times 40.64 cm \times 40.64 cm, 2.54 cm beam space and 1.27 cm spatial resolution) for 90 min to test locomotor activity weekly, during treatment weeks 1–11 and abstinence weeks 1–5. Tests were performed during the dark cycle between the hours of 11:00 and 17:00. Open field locomotor data was acquired with Tru Scan v2.0 software, and activity measures tested included: a) floor plane (FP) moves (the total number of start to stop movements in the X–Y plane, regardless of length or distance of movement); b) floor plane (FP) distance traveled; c) floor plane (FP) velocity; d) vertical plane (VP) entries (the total number of times the rat enters the vertical plane); e) vertical plane (VP) time (the total time the rat spends in the vertical plane); f) center entries (the number of times the rat enters the center of the arena); g) relative center distance traveled (distance traveled in the center of the arena in relation to distance traveled in the 1.9 cm margin of the arena); and h) relative center time (time spent in the center of the arena in relation to time spent in the 1.9 cm margin of the arena).

2.3.4.3. *Circadian activity.* Rats were tested for circadian locomotor activity: a) towards the end of chronic MP treatment (treatment weeks 12–13), and b) during the last week of the abstinence period, which was preceded by chronic MP treatment. Circadian activity was measured for three consecutive days in cages similar to their home cages (50 cm \times 25 cm \times 30 cm high) (Mini Mitter VitalView software; Bend, Oregon). The first day was used for habituation to the experimental room; this data was discarded, and the remaining two days of data were averaged for each animal to obtain activity levels over a 24-hour period. Throughout the three day experiment, food was provided ad libitum, and the 8 h limited access drinking paradigm was kept in place.

2.3.4.4. *Statistical analysis.* For the first experiment (determination of clinically relevant dosing regimens of MP), differences in the consumption of MP solutions were analyzed using a two-way ANOVA [between-subjects factors: drug; time (hour post-initiation of drinking)], and differences in locomotor activity were assessed with a two-way repeated measures ANOVA [between-subjects factor: drug; within-subjects factor: time (hour post-initiation of drinking)]. For the second experiment (determination of developmental and behavioral effects of chronic MP and abstinence), differences in body weight, food intake, and open field measures were assessed with two-way repeated measures ANOVA [between-subjects factor: drug; within-subjects factor: time (week of treatment or abstinence)]. Hourly circadian activity was assessed during treatment and abstinence separately with two-way repeated measures ANOVA [between-subjects factor: drug; within-subjects factor: time (hour of the day)]. Additionally, light and dark

cycle circadian activity was assessed during treatment and abstinence with three-way repeated measures ANOVA [between-subjects factor: drug; within-subjects factors: cycle (light vs. dark cycle) and time (treatment vs. abstinence)]. When appropriate, post-hoc tests were performed to assess pairwise comparisons using the Holm–Sidak method. Statistical significance was set at $\alpha = 0.05$ for all tests.

3. Results

3.1. Determination of clinically relevant dosing regimens of MP

3.1.1. Consumption of MP solutions

All groups of rats were tested for their fluid consumption throughout the 8 hour drinking period (Fig. 1). A two-way ANOVA showed that there was a significant effect of drug [$F(6,378) = 3.713$; $p < 0.01$]. While none of the MP treatment doses resulted in decreased consumption compared to water, rats drinking the 20/30 mg/kg MP solution drank less than some of the other MP groups [20 mg/kg MP ($p < 0.01$), 30 mg/kg MP ($p < 0.01$), and 60 mg/kg MP ($p < 0.001$)].

3.1.2. MP plasma levels

Racemic (D + L) MP plasma levels for all of the groups were tested over time (Fig. 2A). Rats treated with the 30/60 mg/kg MP dual dosage exhibited the highest plasma levels which peaked at ~ 30 ng/mL. Plasma levels of rats treated with 4/10 mg/kg peaked at ~ 8 ng/mL. The 20 mg/kg MP group delivered the lowest plasma levels, averaging less than 5 ng/mL. Other dosages peaked between ~ 10 and 20 ng/mL. In addition to racemic MP levels, the concentrations of the D- and L-isomers of MP were assayed and plotted separately (Fig. 2B–C).

3.1.3. Locomotor activity

Pharmacodynamic effects of MP treatment were assessed by measuring change in locomotor activity from baseline ($t = 0$ h post-initiation of drinking) across the 8 hour drinking period and beyond (Fig. 3). A two-way repeated measures ANOVA revealed a significant main effect of drug [$F(6,312) = 5.297$, $p < 0.001$], with pairwise comparisons showing that overall the 30/60 mg/kg group was more active than the water group ($p < 0.05$), and the 20 mg/kg MP group was less active than the water group ($p < 0.01$). The main effect of time was also significant [$F(6,312) = 18.346$, $p < 0.001$], such that overall, rats were less active at $t = 10$ compared to all other time points ($p < 0.001$ for all), and that rats were more active at $t = 4$ and $t = 6$ compared to $t = 0$ and $t = 8$ ($p < 0.05$ for all). Additionally, the treatment \times time interaction was significant [$F(36,312) = 2.565$, $p < 0.001$]. Rats on 30/60 mg/kg MP were more active than rats treated with water at $t = 2, 4$, and 6, and




Fig. 1. Mean (+ SEM) volume consumption (mL) across treatment groups. Overall, no MP treatment group drank significantly different volumes compared to water-treated rats.




Fig. 2. A. Mean (+SEM) racemic (D + L) MP plasma levels (ng/mL) across treatment groups. The 30/60 mg/kg dual dosage produced the highest racemic MP plasma concentration (~30 ng/mL) within the clinically-relevant spectrum, while the 4/10 mg/kg dual dosage produced a peak concentration of ~8 ng/mL, which corresponds to the optimal plasma concentration produced in the clinical scenario. B. Mean (+SEM) D-isomer MP plasma levels (ng/mL) across treatment groups. C. Mean (+SEM) L-isomer MP plasma levels (ng/mL) across treatment groups.




Fig. 3. Mean (+SEM) percent change in locomotor activity (beam breaks) from baseline across all treatment groups. There were significant treatment effects at various time points after the initiation of drinking. *, 30/60 mg/kg > water; \$, 60 mg/kg > water; Q, 20 mg/kg < water; ^, water > 20, 30, 60, and 20/30 mg/kg.

3.1.4. Determination of developmental and behavioral effects of chronic MP and abstinence

3.1.4.1. *Body weight.* Body weight was measured daily throughout treatment and abstinence periods, and weekly averages were computed (Fig. 4). A two-way repeated measures ANOVA revealed that there was a significant main effect of time on body weight [F(17,993) = 3323.437; p < 0.001], such that rats gained weight as they grew from adolescents to adults. There was also a significant main effect of drug body weight [water > LD and HD MP (p < 0.01 for both), LD > HD MP (p < 0.05)]. The drug × time interaction produced a significant effect on body weight as well [F(34,993) = 6.606; p < 0.001]. Water treated rats weighed significantly more than both LD (treatment weeks 5–13) and HD (treatment weeks 2–13) MP rats (p < 0.05 for all). Water treated rats also weighed significantly more than both MP treated groups throughout all weeks of abstinence (p < 0.05 for all). HD MP rats also weighed less than LD MP rats during treatment weeks 2–13 (p < 0.05 for all).

3.1.4.2. *Food intake.* Food intake was measured daily throughout treatment and abstinence periods, average weekly intake was computed (Fig. 5). A two-way repeated measures ANOVA found that time had a significant main effect on food intake [F(17,993) = 68.573; p < 0.001], with food intake generally increasing during the treatment period as rats grew from adolescents to adults, and reaching a plateau during the abstinence period in adulthood. There was also a significant drug × time interaction effect on food intake [F(34,993) = 3.983; p < 0.001]. Water treated rats ate significantly more than both LD (treatment weeks 1–5) and HD (treatment weeks 4–5 and 9–10) MP rats during early treatment (p < 0.05 for all). HD MP rats also ate less than LD MP rats during treatment weeks 1–2 (p < 0.05 for both).

3.1.4.3. *Open field.* Rats were run in the open field for 90 min once per week during treatment and abstinence periods. A two-way repeated measures ANOVA found that there was a main effect of time on floor plane (FP) moves [F(15,855) = 3.433; p < 0.001; Fig. 6A], and the effect of drug was significant as well [F(2,855) = 12.284; p < 0.001], such that HD MP rats exhibited fewer FP moves than both LD MP and water treated rats (p < 0.001 for both). The drug × time interaction was also significant [F(30,855) = 3.476; p < 0.001]. HD MP treated rats performed a

60 mg/kg rats were more active than water treated rats at t = 6 (p < 0.05 for all). Treatment with 20 mg/kg resulted in hypoactivity compared to water treated rats at t = 2, 4, and 8 (p < 0.05 for all). At t = 10, animals treated with 20, 30, 20/30, and 60 mg/kg MP doses were less active than rats treated with water (p < 0.05 for all).




Fig. 4. Mean (+SEM) body weight by treatment group during MP treatment and abstinence periods. Rats expectedly gained weight as they grew from adolescents to adults. MP treatment dose-dependently attenuated body weight through most of the treatment period. Control rats weighed significantly more than both LD (\$ $p < 0.05$) and HD (* $p < 0.05$) MP rats in treatment weeks 5–13 and 2–13, respectively, and throughout all weeks of abstinence. HD MP rats also weighed less than LD MP rats during treatment weeks 2–13 (# $p < 0.05$).

338 greater number of moves than both LD MP and water treated rats in
339 treatment weeks 1–9 and 11 ($p < 0.05$ for all).

340 A two-way repeated measures ANOVA found that there was a signif-
341 icant effect of drug on floor plane (FP) distance traveled [$F(2,855) =$
342 7.936 ; $p < 0.001$; Fig. 6B]; HD MP rats traveled a greater distance in
343 the open field than both LD MP ($p < 0.05$) and water ($p < 0.001$) treated
344 rats. The main effect of time was also significant [$F(15,971) = 11.775$;
345 $p < 0.001$], with activity decreasing throughout the treatment and absti-
346 nence periods. The drug \times time interaction also reached significance for
347 FP distance traveled [$F(30,855) = 1.7366$; $p < 0.01$]. HD MP treated rats
348 traveled a greater distance than both LD MP (treatment weeks 4, 7, and
349 9–11) and water (treatment weeks 4–11) treated rats ($p < 0.05$ for all).

A two-way repeated measures ANOVA found that the main effect of 350
drug on floor plane (FP) velocity was significant [$F(2,855) = 14.010$;
351 $p < 0.001$; Fig. 6C], with HD MP rats moving at a greater velocity than 352
both LD MP ($p < 0.01$) and water ($p < 0.001$) treated rats. Time also 353
had a significant main effect on velocity [$F(15,855) = 3.464$;
354 $p < 0.001$], such that rats moved with decreasing speed during absti- 355
nence weeks compared to treatment weeks. 356

A two-way repeated measures ANOVA revealed a significant main 357
effect of time on vertical plane entries [$F(15,855) = 20.452$; $p < 0.001$;
358 Fig. 6D], with an increase in behavior from weeks 1 through 7, and 359
remaining steady thereafter through the abstinence period. The 360
drug \times time interaction also had a significant effect on vertical plane 361




Fig. 5. Mean (+SEM) daily food intake by treatment group during MP treatment and abstinence periods. Generally, food intake increased over time as rats grew from adolescents to adults. MP treatment decreased food intake during some of the treatment period, particularly the first few weeks. Control rats ate significantly more than both LD (\$ $p < 0.05$) and HD (* $p < 0.05$) MP rats in treatment weeks 1–5, and 4–5 and 9–10, respectively. HD MP rats also ate less than LD MP rats during treatment weeks 1–2 (# $p < 0.05$).

entries [F(30,855) = 1.773; $p < 0.05$]. HD MP rats exhibited significantly fewer rearing events than both LD MP (treatment weeks 1–3, 5, and 8) and water (treatment weeks 4 and 8) treated rats ($p < 0.05$ for all).

A two-way repeated measures ANOVA revealed a significant main effect of drug on vertical plane time [F(2,855) = 6.529; $p < 0.01$; Fig. 6E], such that HD MP rats displayed less rearing time than both water and LD MP treated rats ($p < 0.01$ for both). The main effect of time was also significant [F(15,855) = 44.447; $p < 0.001$], with an increase in rearing from weeks 1 through 7, and remaining steady thereafter through the abstinence period. The drug \times time interaction also produced significant effects [F(30,971) = 1.928; $p < 0.05$]. HD MP rats spent significantly less time rearing compared to both LD MP (treatment weeks 2, 4–9, and abstinence week 2) and water (treatment weeks 2, 4–9, and 11) treated rats ($p < 0.05$ for all).

A two way repeated measures ANOVA found that drug had a significant main effect on center entries [F(2,855) = 5.884; $p < 0.01$; Fig. 6F], such that HD ($p < 0.01$) and LD ($p < 0.05$) MP rats entered the center of the arena more than water treated rats during open field runs. Time also had a significant effect [F(15,855) = 13.085; $p < 0.001$], with a pattern of rats increasing center entries through treatment weeks, followed by a subsequent decrease in abstinence weeks.

It could be speculated that the MP rats appeared to display increased center activity simply because they exhibited greater general floor plane activity. Therefore, additional two way repeated measures ANOVAs were performed to assess time spent in the center of the arena compared to the margin of the arena (Fig. 6G), as well as distance traveled in the center vs. margin of the arena (Fig. 6H), to determine relative center activity. There was a significant main effect of drug on both relative center distance [F(2,855) = 6.882; $p < 0.01$] and time [F(2,855) = 3.576; $p < 0.05$]. While HD rats expressed greater relative center distance compared to both LD MP and water treated rats ($p < 0.01$ for both), pairwise comparisons showed no significant differences between groups on relative center time. The main effect of time was significant as well for relative center distance [F(15,855) = 38.373; $p < 0.001$] and time [F(15,855) = 32.580; $p < 0.001$], with a general pattern of increasing relative center activity for both measures. The drug \times time interaction effects were also significant for relative center distance [F(30,855) = 2.440; $p < 0.001$] and relative center time [F(30,855) = 2.440; $p < 0.001$]. HD rats traveled a greater relative distance in the center of the arena compared to LD MP and water treated rats in treatment weeks 10–11 and in the second and fifth weeks of abstinence ($p < 0.01$ for all). HD rats spent more time in the center of




Fig. 6. A: Mean (+ SEM) floor plane moves performed in the open field by treatment group during MP treatment and abstinence periods. HD MP treated rats performed a greater number of moves than both LD MP and water treated rats overall ($p < 0.001$ for both), and in treatment weeks 1–9 and 11 ($p < 0.05$ for all). *HD < water, #HD < LD. B: Mean (+ SEM) floor plane distance traveled in the open field by treatment group during MP treatment and abstinence periods. HD MP treated rats traveled a greater distance than both LD MP ($p < 0.05$) and water ($p < 0.001$) treated rats overall, and in treatment weeks 4, 7, and 9–11 (# $p < 0.05$) and 4–11 (* $p < 0.05$), respectively. C: Mean (+ SEM) floor plane (FP) velocity in the open field by treatment group during MP treatment and abstinence periods. Overall, HD MP treated rats traveled at a greater velocity than both LD MP ($p < 0.05$) and water ($p < 0.001$) treated rats. D: Mean (+ SEM) vertical plane entries in the open field by treatment group during MP treatment and abstinence periods. HD MP rats exhibited significantly fewer rearing events than both LD MP and water treated rats in treatment weeks 1–3, 5, and 8 (# $p < 0.05$) and 4 and 8 (* $p < 0.05$), respectively. E: Mean (+ SEM) vertical plane time in the open field by treatment group during MP treatment and abstinence periods. HD MP rats spent significantly less time rearing compared to both LD MP and water treated rats overall ($p < 0.01$) and in treatment weeks 2, 4–9, and abstinence week 2 (# $p < 0.05$) and treatment weeks 2, 4–9, and 11 (* $p < 0.05$), respectively. F: Mean (+ SEM) center entries in the open field by treatment group during MP treatment and abstinence periods. Overall, HD ($p < 0.01$) and LD ($p < 0.05$) MP rats entered the center of the arena more than water treated rats during open field runs. G: Mean (+ SEM) distance traveled in the center vs. margin of the open field arena by treatment group (center distance/margin distance) during MP treatment and abstinence periods. HD rats traveled a greater distance in the center of the arena compared to LD MP (# $p < 0.01$) and water (* $p < 0.01$) treated rats in treatment weeks 10–11 and in the second and fifth weeks of abstinence. H: Mean (+ SEM) time spent in the center vs. margin of the open field arena by treatment group (center time/margin time) during MP treatment and abstinence periods. HD rats spent more time in the center of the arena compared to water treated rats in treatment weeks 10–11 and the second week of abstinence (* $p < 0.01$), and compared to LD rats in treatment weeks 9–11 and the second week of abstinence (# $p < 0.05$).




Fig. 6 (continued).

404 the arena compared to water treated rats in treatment weeks 10–11
 405 and the second week of abstinence (* $p < 0.01$), and compared to LD
 406 rats in treatment weeks 9–11 and the second week of abstinence
 407 (# $p < 0.05$).

408 **3.1.4.4. Circadian activity.** Circadian locomotor activity was measured for
 409 three consecutive days; the first day was used for habituation (data
 410 discarded), and data for last two days were averaged for each animal
 411 (30 minute bins over the 24 hour period). This test was performed during
 412 the last two weeks of MP treatment (Fig. 7A) and during the last
 413 week of the abstinence period (Fig. 7B) on different cohorts of rats.
 414 Separate two-way repeated measures ANOVAs were conducted for
 415 treatment and abstinence. The main effect of drug had significant effects
 416 during MP treatment [$F(2,987) = 20.459$; $p < 0.001$] and abstinence
 417 [$F(2,1551) = 4.738$; $p < 0.02$]: HD MP rats were hyperactive compared
 418 to both water and LD MP treated rats at both times of testing ($p < 0.05$
 419 for all). During both MP treatment [$F(47,987) = 28.490$; $p < 0.001$]
 420 and abstinence [$F(47,1551) = 42.694$; $p < 0.001$], time had a significant
 421 main effect on circadian activity, such that rats displayed normal varia-
 422 tion in activity levels characteristic of rodents throughout the circadian
 423 cycle. The drug \times time interaction produced significant effects on circa-
 424 dian activity during MP treatment [$F(94,987) = 4.309$; $p < 0.001$]. HD
 425 MP treatment resulted in increased activity compared to both LD MP
 426 (09:30–19:00 h) and water (09:00–17:30 h) treatment at specific
 427 times during the dark cycle. LD MP treatment decreased activity com-
 428 pared to water treated rats at a few time points during the dark cycle,
 429 10:00–10:30 and 13:00–13:30 ($p < 0.05$ for both).

430 Additionally, total activity was calculated during the dark and light
 431 cycles during MP treatment and abstinence. A three-way repeated mea-
 432 sures ANOVA revealed a significant main effect of drug [$F(2,54) =$
 433 37.847 ; $p < 0.001$], such that HD rats were more active than LD and
 434 water treated rats ($p < 0.001$ for both). There was also a significant
 435 drug \times time interaction [$F(2,54) = 8.289$; $p < 0.001$], with HD rats on
 436 MP treatment being more active than any other treatment groups at




437 either time point (treatment or abstinence) ($p < 0.01$ for all). Addition- 437
 438 ally, previously treated HD rats were more active than previously treated 438
 439 LD rats during abstinence ($p = 0.01$). The main effect of cycle was 439
 440 significant [$F(1,54) = 797.610$; $p < 0.001$], with rats being more active 440
 441 during the dark cycle compared to the light cycle ($p < 0.001$). The 441
 442 cycle \times drug interaction was also significant [$F(2,54) = 50.001$; 442
 443 $p < 0.001$]. All treatment groups were more active in the dark cycle com- 443
 444 pared to the light cycle ($p < 0.001$ for all), and dark cycle activity exhib- 444
 445 ited by HD rats was greater compared to both water and LD rats 445
 446 ($p < 0.001$ for both). The cycle \times time interaction was significant as 446
 447 well [$F(2,54) = 16.856$; $p < 0.001$]. During both treatment and absten- 447
 448 tence, rats were more active during the dark cycle than the light cycle 448
 449 ($p < 0.001$ for both). Additionally, rats were more active during treat- 449
 450 ment compared to abstinence during the dark cycle only ($p < 0.05$). 450
 451 Lastly, the drug \times cycle \times time interaction was significant [$F(2,54) =$ 451
 452 18.681 ; $p < 0.001$]. During treatment, HD MP resulted in increased activ- 452
 453 ity and LD MP resulted in decreased activity during the dark cycle 453
 454 ($p < 0.05$ for both). During abstinence, previously treated HD rats 454
 455 were more active during the dark cycle than water and previously treated 455
 456 LD MP rats ($p < 0.05$ for both). Dark cycle activity of HD MP rats was 456
 457 attenuated following abstinence compared to treatment levels 457
 458 ($p < 0.05$) (Table 1). 458

4. Discussion

459
 460 The increasing use and abuse of MP, particularly during critical 460
 461 stages of neurodevelopment, presents concerns of subsequent 461
 462 neurobiological, developmental, and behavioral effects and makes nec- 462
 463 essary preclinical studies that can better assess the extent and mecha- 463
 464 nism of these effects. Although rodent studies have been conducted, a 464
 465 vast majority of these studies administer MP in a way that is not rele- 465
 466 vant to clinical applications [e.g. intravenously (IV), intraperitoneally 466
 467 (IP), or subcutaneously], and even studies using oral dosing are incon- 467
 468 sistent in achieving and maintaining clinically-relevant plasma MP 468

469 concentrations (Kuczenski and Segal, 2005) (Wargin et al., 1983;
 470 Gerasimov et al., 2000; Kuczenski and Segal, 2001; Ding et al., 2004).
 471 Therefore, the aim of the current study was to establish and describe a

paradigm for the oral administration of MP in rats that would better 472
 mimic the clinical scenario and determine developmental and behav- 473
 ioral consequences of chronic treatment and abstinence. 474



t1.1 **Table 1**
t Q3 SPM results.

t1.3	Cluster-level			Peak-level				
	P _{FWE-corr}	Q _{FDR-corr}	K _E	P _{uncorr}	T	Z	mm mm mm	Region
t1.5	RYGB (chow < bacon)							
t Q4	0.01	0.01	1390	<0.001	41.32	4.75	1.8 5.6 – 12.8	Right cerebellum (lob. 8)
t1.7				<0.001	19.33	4.1	2.0 7.4 – 8.6	Right MPB, DMTg
t1.8				<0.001	18.53	4.05	0.5 5.5 – 13.0	Midline cerebellum (lob. 8)
t1.9	High-fat diet (AL) (chow < bacon)							
t1.10	0.022	0.015	1499	<0.001	16.02	4.3	2.2 1.4 – 7.4	Retrosplenial cortex (RS)/left primary visual cortex (V1M)
t1.11				<0.001	15.9	4.29	3.4 2.5 – 9.8	Left cerebellum (Sim)
t1.12				<0.001	14.8	4.21	4.0 3.5 – 10.2	Left cerebellum (SimB)

t1.14 Statistical parametric mapping (SPM) results showing significant clusters and statistical parameters for the contrast bacon > chow in rats that underwent gastric bypass surgery (RYGB)
t1.15 and sham-operated controls (AL). The contrast chow > bacon did not yield any significant clusters. (MPB) medial parabrachial nucleus, (DMTg) dorsomedial tegmental area, (Sim) simple lobule.

475 4.1. Determination of clinically relevant dosing regimens of MP

476 MP plasma levels of rats from each treatment group were assessed
477 between 1 and 10 h post-initiation of drinking to determine which
478 treatments best model the pharmacokinetic profile of MP used in clinical
479 applications. When MP is used to treat ADHD in children, oral doses
480 of 0.25–1 mg/kg MP are prescribed, which result in plasma concentra-
481 tions of 8–40 ng/mL (Swanson et al., 1999; Swanson and Volkow,
482 2002). The highest dual bottle dosage (30/60 mg/kg; HD) produced
483 the greatest racemic MP plasma concentration, with the mean plasma
484 concentration peaking at just over 30 ng/mL by the end of the eight-
485 hour drinking period, which is near the higher range of the clinical
486 spectrum. Studies suggest that the full pharmacodynamic and
487 therapeutic effects of MP are a result of the D-isomer (Srinivas
488 et al., 1992; Davids et al., 2002; Ding et al., 2004; Quinn, 2008),
489 while the L-MP isomer seems to have little to no effect on the behav-
490 ioral effects of MP (Markowitz and Patrick, 2008). Therefore,
491 assaying the D- and L-isomers of MP separately was necessary to fully
492 understand the pharmacokinetic profiles of these dosages. The HD
493 treatment also produced the highest plasma concentration of the
494 functional D-isomer, peaking at nearly 25 ng/mL by hour eight,
495 which is at the high range of concentrations that has been seen to be
496 produced in clinical studies (Teicher et al., 2006). Additionally, HD
497 treatment produced the greatest increase in locomotor activity over
498 the drinking period. Locomotor activity exhibited by this group was stably
499 increased over controls between hours two and six post-initiation of
500 drinking and peaked at hour four, indicating a robust and long-lasting
501 pharmacodynamic effect. Taken together, these findings suggest that
502 this 30/60 mg/kg dual dosage would be useful in future MP experiments
503 as a clinically relevant high dose.

504 The lowest dual bottle dosage of 4/10 mg/kg (LD) resulted in a race-
505 mic MP plasma concentration that peaks at about 8 ng/mL. This concen-
506 tration is comparable to clinically-used oral doses of approximately
507 0.3 mg/kg, which lead to plasma concentrations of approximately
508 8–10 ng/mL in children (Swanson et al., 1999). This dual dosage pro-
509 duced a peak D-MP concentration between 4 and 5 ng/mL in plasma,
510 which in humans has been shown to block about 50% of striatal dopa-
511 mine transporter (Volkow et al., 1998), while having no significant ef-
512 fect on locomotor activity. Therefore, in the paradigm reported here,
513 pharmacokinetic profiles are produced in the rat with oral dosing of
Q22 MP that mimics those formulations now in clinical use to treat ADHD

and thus present a valuable animal model of studying the effects of 515
MP treatments in rodent models. 516

517 We observed a trend such that the drinking behavior of rats on an 518
8 hour restricted drinking regimen were marked by high consumption 519
in the first hour, followed by a steady consumption of smaller amounts 520
over the next few hours with a smaller peak later, in agreement with 521
one of our previous studies (Thanos et al., 2004). Due to this consump- 522
tion pattern, an initial bolus-like dosage could be delivered, followed by 523
steady and then slightly increased intake to maintain this peak effect, 524
which is similar to the delivery design of commonly prescribed drugs 525
shown to be effective in treating ADHD (Swanson et al., 2002). Addi- 526
tionally, we found that administering MP in rats' drinking water does 527
not appear to significantly alter fluid consumption, which is in agree- 528
ment with both early preclinical (Barone et al., 1979) and clinical 529
(Conners, 1975) studies.

530 4.2. Determination of developmental and behavioral effects of chronic MP 531 and abstinence

532 We then tested these two clinically relevant dual dosage paradigms 533
[4/10 mg/kg (LD) and 30/60 mg/kg (HD) MP] to assess their effects on 534
development and behavior following chronic treatment and abstinence.

535 Methylphenidate (MP) decreased food intake during early weeks of 536
treatment, suggesting that MP is an appetite suppressant, particularly in 537
the short-term. MP treatment also dose-dependently decreased body 538
weight compared to the water group. During abstinence, body weight 539
of HD MP rats rebounded to that of LD MP rats; however, both groups 540
still weighed significantly less than water treated rats. These findings 541
agree with previous studies that have shown that MP treatment reduces 542
appetite and food intake, and results in weight loss in rodents and 543
humans (Heffner et al., 1977; Vanina et al., 2002; Leddy et al., 2004; 544
Gray et al., 2007). Our study found that the effects of MP on body 545
weight, however, far outlast its effects on appetite, which suggests 546
that MP may reduce body weight by increasing energy expenditure, 547
speeding metabolism and/or suppressing growth. Additionally, the at- 548
tenuation of body weight persisted throughout abstinence. Clinical 549
studies have found that stimulant treatment of ADHD results in de- 550
creased height and body weight, though these effects were ameliorated 551
with the cessation of treatment, and ultimate growth parameters were 552
not affected (Safer et al., 1972; Mattes and Gittelman, 1983; Faraone 553
et al., 2008). It is also possible that our treatment did affect ultimate

Fig. 7. A: Mean (+SEM) activity over the circadian cycle by treatment group during MP treatment. A normal circadian cycle was exhibited by all groups, with no apparent shift in cycle. HD MP treatment resulted in hyperactivity compared to both LD MP and water treatment overall ($p < 0.05$), and at specific times during the dark cycle: 09:00–17:30 ($\#p < 0.05$) and 09:30–19:00 ($\#p < 0.05$), respectively. LD MP treatment decreased activity compared to controls at a few time points during the dark cycle, 10:00–10:30 and 13:00–13:30 ($\$p < 0.05$). **B:** Mean (+SEM) activity over the circadian cycle by treatment group during abstinence. A normal circadian cycle was exhibited by all groups, with no apparent shift in cycle. HD MP treatment resulted in hyperactivity compared to both LD MP and water treatment overall ($p < 0.05$). **C:** Mean (+SEM) total activity during the dark and light cycles by treatment group during treatment (TX) and abstinence (AB). During treatment, HD MP resulted in increased activity (vs. water $\#p < 0.001$; vs. LD MP $\#p < 0.001$) and LD MP resulted in decreased activity during the dark compared to water ($\$p < 0.05$). During abstinence, previously-treated HD rats were more active during the dark cycle than water ($\#p < 0.01$) and previously-treated LD MP rats ($\#p < 0.01$). Dark cycle activity of HD MP rats was greater during treatment than during abstinence ($\#p < 0.001$).

growth parameters or that the abstinence period was not long enough to see a rebound effect. It appears that the clinical effects of MP on reducing body weight may be less drastic than that observed here, possibly due to the drug's locomotor-attenuating effect (reduced energy expenditure) in treated patients.

Open field activity was recorded once per week during treatment and abstinence periods. During most of the treatment period, HD MP rats displayed hyperactivity compared to controls, as measured by distance traveled. These effects were greatest during later weeks, suggesting sensitization to the drug, which is in agreement with previous studies (Kuczenski and Segal, 2001; Yang et al., 2003). Displays of behavioral sensitization to a psychostimulant present concerns, as it provides evidence for persistent neurological changes in circuitry involved in motivation and reward (Robinson, 1993). While open field velocity was also increased by HD MP treatment, the number of floor plane moves performed by this treatment group was reduced. These results suggest that HD MP treatment likely results in increased ambulation rather than stereotypic-like behavior.

HD MP treatment also reduced rearing activity in the open field (vertical plane entries and time), with behaviors normalizing during abstinence. Attenuated rearing during MP treatment is in agreement with a previous study (Wultz et al., 1990), and it is possible that the MP-induced hyperactivity in the horizontal plane hindered vertical plane activity, though MP has been shown to increase both measures in some cases (Izenwasser et al., 1999). Rearing can also be an indicator of exploratory behavior, and interpreting this behavior as such is in agreement with previous findings that MP treatment diminishes exploration, as well as preference for novelty (Hughes, 1972; Mislin and Ropartz, 1981; Heyser et al., 2004).

It was also seen that HD MP treated rats displayed increased center activity (center entries, relative center distance, and relative center time) compared to the water group during the treatment period, specifically during later weeks of treatment. Increased center activity is an indicator of an anxiolytic effect (Fernández-Teruel et al., 1992). This is in agreement with previous studies on rats that have found that MP treatment decreases anxiety in other tests, such as the elevated plus maze (Zhu et al., 2010). It has also been reported that clinically treated ADHD patients taking MP report decreased anxiety (Barrickman et al., 1995; Bouffard et al., 2003). It is also possible that cognitive processes (e.g. attention) were negatively affected by MP treatment in these animals, leading to poor discrimination of "safe" versus "unsafe" areas. MP's deleterious effects on cognitive processes in non-ADHD rodent models have been demonstrated previously (Ferguson et al., 2007; Thanos et al., 2010). Therefore, it would be beneficial to assess additional aspects of anxiety (e.g. social anxiety) in the future.

Circadian activity testing showed that all MP groups, during treatment and abstinence, exhibited a generally normal pattern of circadian activity, with rats being more active during the dark cycle than the light cycle. MP treatment did, however, affect activity levels during the dark phase. During treatment, LD MP decreased activity at a few time points in the early to mid-dark phases, as well as total activity in the dark phase. This is in agreement with a previous study that found that low doses of oral MP have been shown to decrease activity in rodents when given at a dosage that produces comparable plasma concentrations (Kuczenski and Segal, 2002). We did not see this effect in the open field, possibly because circadian tests were performed in a home cage-like setting, while open field tests were performed in a different environment. In contrast, HD MP treatment resulted in hyperlocomotion throughout most of the dark phase, corroborating open field results. Activity levels of LD MP rats returned to normal following the abstinence period, while those of HD MP rats were reduced but remained significantly elevated over controls in the dark phase. These results suggest that chronic MP treatment increases the magnitude of activity during the dark cycle, but does not alter or shift the pattern of circadian activity. Light cycle activity remained unaffected, suggesting that these doses of MP do not inhibit normal sleep. Despite

concern over MP-induced sleep disturbances (Schwartz et al., 2004; Sangal et al., 2006), our findings are in agreement with previous clinical studies, which found that MP had no significant effect on multiple sleep parameters (Tirosh et al., 1993; Kent et al., 1995). It is possible that sleep disturbances are not seen due to our dosing schedule (dosing ended at 17:00 h and the light cycle began at 20:00 h) and the speed of MP's metabolism in rats compared to humans (~1 h vs. ~3 h, respectively) (Patrick et al., 1984; Aoyama et al., 1990; Patrick and Markowitz, 1997; Thai et al., 1999).

5. Conclusion

The impetus for this study was the concern about the widespread prescribed or illicit use of MP by both children and adults. Concerns have arisen regarding chronic MP exposure, since it may produce long-term developmental or behavioral effects, as well as sensitization to the effects of other psychostimulants such as cocaine or methamphetamine, leading to an increased vulnerability to stimulant abuse later in life (Volkow et al., 1999; Thanos et al., 2007). The current study found that chronic MP exposure leads to alterations in body weight, food consumption, locomotor activity, and measures of exploration and anxiety, with some of these measures being affected even after an extended period of abstinence. Results suggest the need for studies with longer treatment length, as many observed effects took several weeks to appear, and most prior studies on MP have only dosed for ~1–2 weeks or less. Additional pharmacokinetic studies of MP metabolism in females and in different strains of rats will need to be performed, as first-pass hepatic metabolism of MP may vary. In conclusion, these results and model provide a critical foundation for further animal studies to examine the effects of acute or chronic MP administration.

Acknowledgments

This work was supported by NIAAA and NICHD.

References

- Aoyama T, Kotaki H, Iga T. Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. *J Pharmacobiodyn* 1990;13:647.
- APA. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, D.C.: American Psychiatric Association; 2013.
- Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. *Contemp Top Lab Anim Sci* 2004;43:42–51.
- Barone F, Wayner M, Lee H, Tsai W, Dehaven D, Woodson WJ. Effects of methylphenidate on food and water consumption at different body weights. *Pharmacol Biochem Behav* 1979;10:591–5.
- Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1995;34:649–57.
- Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2011. National Center for Health Statistics. *Vital Health Stat* 2012;10.
- Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. *Curr Drug Abuse Rev* 2009;2:157–76.
- Bouffard R, Hechtman L, Minde K, Laboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. *Can J Psychiatry* 2003;48:546–54.
- Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. *Biol Psychiatry* 2003;54:1338–44.
- Brandon CL, Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. *Eur J Neurosci* 2003;18:1584–92.
- Brown AP, Dinger N, Levine BS. Stress produced by gavage administration in the rat. *Contemp Top Lab Anim Sci* 2000;39:17–21.
- Conners CK. Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. *Int J Ment Health* 1975;61–74.
- David E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. *Psychopharmacology (Berl)* 2002;160:92–8.
- Ding YS, Gatley SJ, Thanos PK, Shea C, Garza V, Xu Y, et al. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. *Synapse* 2004;53:168–75.
- Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. *J Am Acad Child Adolesc Psychiatry* 2008;47:994–1009.
- Ferguson SA, Paule MG, Cada A, Fogle CM, Gray EP, Berry KJ. Baseline behavior, but not sensitivity to stimulant drugs, differs among spontaneously hypertensive,

- 689 Wistar–Kyoto, and Sprague–Dawley rat strains. *Neurotoxicol Teratol* 2007;29:
690 547–61.
- 691 Fernández-Teruel A, Escorihuela R, Driscoll P, Tobeña A, Bättig K. Differential effects of
692 early stimulation and/or perinatal flumazenil treatment in young Roman low- and
693 high-avoidance rats. *Psychopharmacology (Berl)* 1992;108:170–6.
- 694 Garnier-Dykstra LM, Caldeira KM, Vincent KB, O'Grady KE, Arria AM. Nonmedical use of
695 prescription stimulants during college: four-year trends in exposure opportunity,
696 use, motives, and sources. *J Am Coll Health* 2012;60:226–34.
- 697 Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al. Compar-
698 ison between intraperitoneal and oral methylphenidate administration: a microdial-
699 ysis and locomotor activity study. *J Pharmacol Exp Ther* 2000;295:51–7.
- 700 Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, et al. Methylphenidate ad-
701 ministration to juvenile rats alters brain areas involved in cognition, motivated be-
702 haviors, appetite, and stress. *J Neurosci* 2007;27:7196–207.
- 703 Grund T, Lehmann K, Bock N, Rothenberger A, Teuchert-Noodt G. Influence of methylphe-
704 nidate on brain development—an update of recent animal experiments. *Behav Brain*
705 *Funct* 2006;2:2.
- 706 Heffner TG, Zigmond MJ, Stricker EM. Effects of dopaminergic agonists and antagonists of
707 feeding in intact and 6-hydroxydopamine-treated rats. *J Pharmacol Exp Ther* 1977;
708 201:386–99.
- 709 Heyser CJ, Pelletier M, Ferris JS. The effects of methylphenidate on novel object explora-
710 tion in weanling and periadolescent rats. *Ann N Y Acad Sci* 2004;1021:465–9.
- 711 Hughes RN. Methylphenidate induced inhibition of exploratory behaviour in rats. *Life Sci* 1
712 1972;11:161–7.
- 713 Izenwasser S, Coy A, Ladenheim B, Loeloff R, Cadet J, French D. Chronic methylphenidate
714 alters locomotor activity and dopamine transporters differently from cocaine. *Eur J*
715 *Pharmacol* 1999;373:187–93.
- 716 Justo CC, Carneiro-de-Oliveira PE, Delucia R, Aizenstein ML, Planeta CS. Repeated expo-
717 sure of adolescent rats to oral methylphenidate does not induce behavioral sensitiza-
718 tion or cross-sensitization to nicotine. *Braz J Med Biol Res* 2010;43:651–6.
- 719 Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphe-
720 nidate administration on behavior and sleep in attention-deficit hyperactivity disor-
721 der. *Pediatrics* 1995;96:320–5.
- 722 Komatsu DE, Thanos PK, Mary MN, Janda HA, John CM, Robison L, et al. Chronic exposure
723 to methylphenidate impairs appendicular bone quality in young rats. *Bone* 2012;50:
724 1214–22.
- 725 Kuczenski R, Segal DS. Locomotor effects of acute and repeated threshold doses of am-
726 phetamine and methylphenidate: relative roles of dopamine and norepinephrine. *J*
727 *Pharmacol Exp Ther* 2001;296:876–83.
- 728 Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential
729 effects on extracellular norepinephrine and absence of sensitization and cross-
730 sensitization to methamphetamine. *J Neurosci* 2002;22:7264–71.
- 731 Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/
732 hyperactivity disorder treatment and potential substance abuse. *Biol Psychiatry*
733 2005;57:1391–6.
- 734 LeBlanc-Duchin D, Taukulis HK. Chronic oral methylphenidate administration to
735 periadolescent rats yields prolonged impairment of memory for objects. *Neurobiol*
736 *Learn Mem* 2007;88:312–20.
- 737 Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, et al. Influence of
738 methylphenidate on eating in obese men. *Obes Res* 2004;12:224–32.
- 739 Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methyl-
740 phenidate enantiomers: does chirality matter? *J Clin Psychopharmacol* 2008;28:
741 554–61.
- 742 Mattes JA, Gittelman R. Growth of hyperactive children on maintenance regimen of
743 methylphenidate. *Arch Gen Psychiatry* 1983;40:317–21.
- 744 McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimu-
745 lant medication. *J Psychoactive Drugs* 2006;38:43–56.
- 746 McCabe SE, Teter CJ, Boyd CJ, Knight JR, Wechsler H. Nonmedical use of prescription opi-
747 oids among U.S. college students: prevalence and correlates from a national survey. *Addict Behav* 2005;30:789–805.
- 748 Misslin R, Ropartz P. Effects of methamphetamine on novelty-seeking behaviour by mice.
749 *Psychopharmacology (Berl)* 1981;75:39–43.
- 750 **Q25** Patrick KS, Ellington KR, Breese GR. Distribution of methylphenidate and p-
751 hydroxymethylphenidate in rats. *J Pharmacol Exp Ther* 1984;231:61–5.
- 752 Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers
753 and pemoline in attention-deficit hyperactivity disorder. *Hum Psychopharmacol Clin*
754 *Exp* 1997;12:527–46.
- 755 Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to
756 amphetamine-like psychostimulants. *Brain Res Brain Res Rev* 1997;25:192–216.
- 757 Quinn D. Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate
758 in patients with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*
759 2008;28:S62–6.
- 760 Robinson TE. Persistent sensitizing effects on drugs on brain dopamine systems and be-
761 havior: implications for addiction and relapse. In: Korenman SG, Barchas JD, editors.
762 *Biological basis of substance abuse*. NY: Oxford University Press; 1993.
- 763 Robinson TE, Berridge KC. Incentive-sensitization and addiction. *Addiction* 2001;96:
764 103–14.
- 765 Robinson L, Ananth M, Swanson J, Robinson J, Wang G-J, Volkow N, et al. Effect of chronic
766 oral methylphenidate treatment and abstinence on dopamine transporter (DAT),
767 D1R, and D2R binding in young rats. Program No. 871.07. 2012 Neuroscience Meeting
768 Planner. New Orleans, LA: Society for Neuroscience, 2012. Online; 2012.
- 769 Robison LS, Ananth M, Johnson S, Clark J, Mummello M, Malitsis NG, et al. Effects of chronic
770 oral methylphenidate exposure on body weight, food intake, circadian activity, open
771 field activity and novel object recognition in rats. Program No. 367.4. 2010
772 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010.
773 Online; 2010.
- 774 Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs.
775 *N Engl J Med* 1972;287:217–20.
- 776 Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and
777 methylphenidate on sleep in children with ADHD. *Sleep* 2006;29:1573–85.
- 778 Schwartz G, Amor LB, Grizenko N, Lageix P, Baron C, Boivin DB, et al. Actigraphic monitor-
779 ing during sleep of children with ADHD on methylphenidate and placebo. *J Am Acad*
780 *Child Adolesc Psychiatry* 2004;43:1276–82.
- 781 Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and
782 pharmacodynamics of DL-threo-methylphenidate in children with attention deficit
783 hyperactivity disorder. *Clin Pharmacol Ther* 1992;52:561–8.
- 784 Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, et al. Acute tolerance to meth-
785 ylphenidate in the treatment of attention deficit hyperactivity disorder in children.
786 *Clin Pharmacol Ther* 1999;66:295–305.
- 787 Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, et al. The use of a labo-
788 ratory school protocol to evaluate concepts about efficacy and side effects of new
789 formulations of stimulant medications. *J Atten Disord* 2002;6(Suppl. 1):S73–88.
- 790 Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimu-
791 lants: implications for the design of new treatments for ADHD. *Behav Brain Res*
792 2002;130:73–8.
- 793 Swanson JM, Volkow ND. Increasing use of stimulants warns of potential abuse. *Nature*
794 2008;453:586.
- 795 Swanson JM, Volkow ND. Psychopharmacology: concepts and opinions about the use of
796 stimulant medications. *J Child Psychol Psychiatry* 2009;50:180–93.
- 797 Teicher MH, Polcari A, Foley M, Valente E, McGreenery CE, Chang VW, et al. Methylphe-
798 nidate, low levels and therapeutic response in children with attention-deficit hyper-
799 activity disorder: I. Effects of different dosing regimens. *J Child Adolesc*
800 *Psychopharmacol* 2006;16:416–31.
- 801 Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription
802 stimulants among college students: prevalence, motives, and routes of administra-
803 tion. *Pharmacotherapy* 2006;26:1501–10.
- 804 Thai DL, Yurasits LN, Rudolph GR, Perel JM. Comparative pharmacokinetics and tissue dis-
805 tribution of the D-enantiomers of para-substituted methylphenidate analogs. *Drug*
806 *Metab Dispos* 1999;27:645–50.
- 807 Thanos P, Bermeo C, Rubinstein M, Suchland K, Wang G, Grandy D, et al. Conditioned
808 place preference and locomotor activity in response to methylphenidate, amphet-
809 amine and cocaine in mice lacking dopamine D4 receptors. *J Psychopharmacol* 2009.
810 **Q27**
- 811 Thanos PK, Ivanov I, Robinson JK, Michaelides M, Wang G-J, Swanson JM, et al. Dissocia-
812 tion between spontaneously hypertensive (SHR) and Wistar–Kyoto (WKY) rats in
813 baseline performance and methylphenidate response on measures of attention, im-
814 pulsivity and hyperactivity in a visual stimulus position discrimination task.
815 *Pharmacol Biochem Behav* 2010;94:374–9.
- 816 Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND. Effects of chronic oral
817 methylphenidate on cocaine self-administration and striatal dopamine D2 receptors
818 in rodents. *Pharmacol Biochem Behav* 2007;87:426–33.
- 819 Thanos PK, Taintor N, Rivera SN, Umegaki H, Ikari H, Roth G, et al. DRD2 gene transfer into
820 the nucleus accumbens of the alcohol preferring (P) and non preferring (NP) rats
821 attenuates alcohol drinking. *Alcohol Clin Exp Res* 2004;28:720–8.
- 822 Tirosh E, Sadeh A, Munvez R, Lavie P. Effects of methylphenidate on sleep in children with
823 attention-deficit hyperactivity disorder: an activity monitor study. *Arch Pediatr*
824 *Adolesc Med* 1993;147:1313.
- 825 Torres-Reveron A, Dow-Edwards DL. Repeated administration of methylphenidate in
826 young, adolescent, and mature rats affects the response to cocaine later in adulthood.
827 *Psychopharmacology (Berl)* 2005;181:38–47.
- 828 Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, et al. Body weight
829 changes associated with psychopharmacology. *Psychiatr Serv* 2002;53:842–7.
- 830 Volkow N, Wang G, Fowler J, Logan J, Gatley S, Wong C, et al. Reinforcing effects of
831 psychostimulants in humans are associated with increase in brain dopamine and oc-
832 cupancy of D2 receptors. *J Pharmacol Exp Ther* 1999;291:409–15.
- 833 Volkow ND, Insel TR. What are the long-term effects of methylphenidate treatment? *Biol*
834 *Psychiatry* 2003;54:1307–9.
- 835 Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphe-
836 nidate in the treatment of ADHD. *Am J Psychiatry* 2003;160:1909–18.
- 837 Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Dopamine transporter
838 occupancies in the human brain induced by therapeutic doses of oral methylphe-
839 nidate. *Am J Psychiatry* 1998;155:1325–31.
- 840 Wargin V, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, et al. Pharmacokinetics
841 of methylphenidate in man, rat and monkey. *J Pharmacol Exp Ther* 1983;226:382–6.
- 842 Wilens T, Adler L, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion
843 of stimulants prescribed for ADHD: a systematic review of the literature. *J Am Acad*
844 *Child Adolesc Psychiatry* 2008;47:21–31.
- 845 Wultz B, Sagvolden T, Moser EI, Moser MB. The spontaneously hypertensive rat as an
846 animal model of attention-deficit hyperactivity disorder: effects of methylphenidate
847 on exploratory behavior. *Behav Neural Biol* 1990;53:88–102.
- 848 Yang PB, Amini B, Swann AC, Dafny N. Strain differences in the behavioral responses of
849 male rats to chronically administered methylphenidate. *Brain Res* 2003;971:139–52.
- 850 Zhu N, Weedon J, Dow-Edwards DL. The multifaceted effects of oral administration
851 of methylphenidate in juvenile rats: anxiety, activity, and attention. *Eur*
852 *Neuropsychopharmacol* 2010;20:236–44.